With a roster of gene therapy vets, Forbion makes a bet on 'relatively empty space' of vectorized antibodies
The future waves of gene therapy could look quite different from the gene replacement offerings currently on the market, Forbion reckons.
It’s the key idea behind VectorY, a startup seeded by the European VC firm that’s out to develop vectorized antibodies for muscular and neurodegenerative disorders.
Voyager Therapeutics, which briefly pushed the technology to the limelight with its short-lived AbbVie collaboration, is among the “several other companies working on it too, but definitely it’s a pretty relatively empty space,” said Marco Boorsma — a general partner at Forbion who’s stepping in as interim CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.